iPS Cells & Regenerative Medicine Weekly Report July 12, 2026

iPS Cells & Regenerative Medicine Weekly Report July 19, 2026

MD Anderson Reports 70% Response Rate with Novel Claudin-18.2-Targeted CAR-T Cell Therapy for Intractable Kidney Cancer

uBriGene Launches uVivo Lentiviral Vector Platform to Accelerate Next-Generation In Vivo CAR T Therapies

Auxilium Biotechnologies Achieves World-First Space Bioprinting of Functional Kidney and Liver Tissues on ISS

Allogene’s ALLO-316 Allogeneic CAR T Achieves First Durable Remissions with 31% ORR in Phase 1 Metastatic Renal Cell Carcinoma Trial

Novel Stem Cell Approach Aims for Functional Cure in Diabetes, Pioneering Immunosuppression-Free Islet Cell Transplantation

Kite and BBG Advanced Therapies Launch Mobile Leukapheresis Center in Texas to Enhance CAR T-Cell Therapy Patient Access and Streamline Supply Chain

Wugen Rebrands as Allotera, Closes $35 Million Financing Round to Accelerate Off-the-Shelf Cell Therapy Development for Cancer and Autoimmune Diseases